Recommendations for the use of medications with continuous enteral nutrition

American Journal of Health-System Pharmacy

Volumn 66, Issue 16, 2009, Pages 1458-1467

  Wohlt, Paul D ^a   Zheng, Lan ^b   Gunderson, Shelly ^c   Balzar, Sarah A ^d   Johnson, Benjamin D ^e   Fish, Jeffrey T ^e  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e University of Wisconsin Health   (United States)

Author keywords

Drug interactions; Nutrition

Indexed keywords

AMINOPHYLLINE; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ATOVAQUONE; AZITHROMYCIN; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CYCLOSPORIN; DIAZEPAM; DILTIAZEM; ESOMEPRAZOLE; FAMOTIDINE; HYDRALAZINE; LANSOPRAZOLE; LANTHANUM; LEVOFLOXACIN; LEVOTHYROXINE SODIUM; LINEZOLID; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN V; PHENYTOIN; POSACONAZOLE; RAPAMYCIN; SEVELAMER; SUCRALFATE; SUSTACAL; TACROLIMUS; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE DIET; CONTINUOUS ENTERAL NUTRITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; ENTERIC FEEDING; EVIDENCE BASED PRACTICE; FOOD; FOOD DRUG INTERACTION; HUMAN; LIPID DIET; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN INTAKE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 69249162704     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080632     Document Type: Article

References (89)

1. Kirby DF, Delegge MH, Fleming CR. American Gastroenterological Association technical review on tube feeding for enteral nutrition. Gastroenterology. 1995; 108:1282-1301
2. Brown RO, Dickerson RN. Drug-nutrient interactions. Am J Manag Care. 1999; 5:345-355
3. Guyett G, Gutterman D, Baumann MH et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest. 2006; 129:174-181
4. Zovirax (acyclovir) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005.
5. Shalansky KF, Vaughan LM, Ustad C et al. Absolute bioavailability of aminophylline liquid administered enterally in adults requiring mechanical ventilation. Clin Pharm. 1992; 11:428-432
6. Pacerone (amiodarone) package insert. Minneapolis: Upsher-Smith Laboratories, Inc., 2004.
7. Augmentin (amoxicillin-clavulanate) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005.
8. Freeman CD, Klutman NE, Lamp KC et al. Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother. 1998; 32:1004-1007
9. Zithromax (azithromycin) package insert. New York: Pfizer Labs; 2004.
10. Clark-Schmidt AL, Garnett WR, Lowe DR et al. Loss of carbamazepine suspension through nasogastric feeding tubes. Am J Hosp Pharm. 1990; 47:2034-2037
11. Sacks G. Drug-nutrient considerations in patients receiving parenteral and enteral nutrition. Pract Gastroenterol. 2004; 28:39-48. (Pubitemid 39166896)
12. Engle KK, Hannawa TE. Techniques for administering oral medication to critical care patients receiving continuous enteral nutrition. Am J Health-Syst Pharm. 1999; 56:1441-1444 (Pubitemid 29331360)
13. Bass J, Miles MV, Tennison MB et al. Effects of enteral tube feeding on the absorption and pharmacokinetic profile of carbamazepine suspension. Epilepsia. 1989; 30:364-369 (Pubitemid 19161400)
14. Kassam RM, Friesen E, Locock RA. In vitro recovery of carbamazepine from Ensure. J Parenter Enteral Nutr. 1989; 13:272-276
15. Rochard EB, Barthes DM, Courtois PY. Stability of cimetidine hydrochloride in Sondalis Iso enteral nutrition formula. Am J Hosp Pharm. 1991; 48:1681-1682
16. De Marie S, VandenBergh MF, Buijk SL et al. Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. Intensive Care Med. 1998; 24:343-346 (Pubitemid 28203883)
17. Mimoz O, Binter V, Jacolot A et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 1998; 24:1047-1051 (Pubitemid 28497822)
18. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother. 1996; 40:6-10.
19. Cohn SM, Sawyer MD, Burns GA et al. Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother. 1996; 38:871-876 (Pubitemid 26413724)
20. Cipro (ciprofloxacin) tablets/suspension package insert. Wayne, NJ: Bayer Health Care; 2008 Oct.
21. Cleocin HCl (clindamycin) package insert. Kalamazoo, MI: Pharmacia & Upjohn Company; 2003.
22. Neoral (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2001.
23. Thomson FC, Naysmith MR, Lindsay A. Managing drug therapy in patients receiving enteral and parenteral nutrition. Hosp Pharm. 2000; 7:155-156
24. Valium (diazepam) tablets package insert. Nutley, NJ: Roche Pharmaceuticals; 2008.
25. Diltiazem. In: Drugdex System [Internet database]. Version 5.1. Greenwood Village, CO: Thomson Healthcare. Updated periodically.
26. Cardizem LA (diltiazem) package insert. Cranbury, NJ: Kos Pharmaceuticals, Inc.; 2006.
27. Nexium (esomeprazole magnesium) package insert. Wilmington, DE: AstraZeneca LP; 2008.
28. Data on file for Pepcid (famotidine). Merck & Co., Whitehouse Station, NJ; 2008.
29. Pepcid (famotidine) package insert. Whitehouse Station, NJ: Merck & Co.; 2007.
30. Nicolau DP, Crowe H, Nightingale CH et al. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother. 1995; 36:395-401.
31. Buijk SL, Gyssens IC, Mouton JW et al. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 2001; 27:115-21.
32. Rosemurgy AS, Markowsky S, Goode SE et al. Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J Trauma. 1995; 39:445-447
33. Semple HA, Koo W, Tam YK et al. Interactions between hydralazine and oral nutrients in humans. Ther Drug Monit. 1991; 13:304-308
34. Sporanox (itraconazole) package insert. Raritan, NJ: Ortho Biotech Products, LP; 2003.
35. Prevacid (lansoprazole) package insert. Lake Forest, IL: TAP Pharmaceuticals Inc.; 2003.
36. Barradell LB, Faulds D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992; 44:225-250
37. Michael RC. Medication errors. Liquid lansoprazole: gumming up the works. Nursing. 2002; 32:14.
38. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension - a liquid formulation of lansoprazole - effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroen terol. 1999; 94:1813-1817 (Pubitemid 29315891)
39. Data on file for Fosrenol (lanthanum). Shire US, Wayne, PA; 2007 Apr.
40. Monica AF, Raj DS, Gidal BE. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. Clin Ther. 2005; 27:594-598
41. Levaquin (levofloxacin) package insert. Raritan, NJ: Ortho-McNeil Pharmaceuticals, Inc.; 2008.
42. Manessis A, Lascher S, Bukberg P et al. Quantifying amount of adsorption of levothyroxine by percutaneous endoscopic gastrostomy tubes. J Parenter Enteral Nutr. 2008; 32:197-200.
43. Smyrniotis V, Vaos N, Arkadopoulos N et al. Severe hypothyroidism in patients dependent on prolonged thyroxine infusion through a jejunostomy. Clin Nutr. 2000; 19:65-67
44. Zyvox (linezolid) package insert. Kalamazoo, MI: Pharmacia & Upjohn Company; 2003.
45. Beringer P, Nguyen M, Hoem N et al. Absolute bioavailability and pharmacokinetics of linezolid in hospital patients given enteral feedings. Antimicrob Agents Chemother. 2005; 49:3676-3681 (Pubitemid 41233017)
46. Ativan (lorazepam) package insert. Corona, CA: Watson Laboratories; 2004.
47. Lopressor (metoprolol tartrate) package insert. Detroit, MI: Caraco Pharmaceutical Labortories, Ltd.; 2007.
48. Metronidazole. In: Drugdex System [Internet database]. Version 5.1. Greenwood Village, CO: Thomson Healthcare. Updated periodically.
49. Burkhardt O, Stass H, Thuss U et al. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet. 2005; 44:969-976 (Pubitemid 41252845)
50. Lettieri J, Vargas R, Agarwal V et al. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet. 2001; 40(suppl 1):19-25. (Pubitemid 32295678)
51. Anaizi NH, Swenson CF, Dentinger PJ. Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 1998; 55:926-929 (Pubitemid 28198774)
52. Cellcept (mycophenolate mofetil) package insert. Nutley, NJ: Roche Laboratories, Inc.; 2004.
53. Omeprazole. In: Drugdex System [Internet database]. Version 5.1. Greenwood Village, CO: Thomson Healthcare. Updated periodically.
54. Zegerid (omeprazole-sodium bicarbonate) package insert. San Diego: Santarus, Inc.; 2008.
55. Phillips JO, Metzler MH, Palmieri TL et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med. 1996; 24:1793-1800
56. Cornish P. "Avoid the crush": hazards of medication administration in patients with dysphagia or a feeding tube. CMAJ. 2005; 172:871-872
57. Protonix (pantoprazole sodium) package insert. Philadelphia: Wyeth Pharmaceuticals, Inc.; 2008.
58. Ferron GM, Ku S, Abell M et al. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health-Syst Pharm. 2003; 60:1324-1329 (Pubitemid 46118102)
59. Dentinger PJ, Swenson CF, Anaizi NH. Stability of pantoprazole in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 2002; 59:953-956 (Pubitemid 34522597)
60. McCarthy CG, Finland M. Absorption and excretion of 4 penicillins: penicillin G, penicillin V, phenethicillin and phenylmercaptomethylpenicillin. N Engl J Med. 1960; 263:315.
61. Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction? Ann Pharmacother. 2000; 34:896-905.
62. Wilder BJ, Leppik I, Hietpas TJ et al. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology. 2001; 57:582-589 (Pubitemid 32782983)
63. Sansone-Parsons A, Krishna G, Calzetta A et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006; 50:1881-1883
64. Crowther RS, Bellanger R, Szauter KE. In vitro stability of ranitidine hydrochloride in enteral nutrient formulas. Ann Pharmacother. 1995; 29:859-862
65. Zantac (ranitidine) package insert. Research Triangle Park, NJ: GlaxoSmithKline; 2007.
66. Data on file for Renagel (sevelamer). Genzyme Corporation, Cambridge, MA; 2005 Sep.
67. McElhiney LF. Sevelamer suspension in children with end-stage renal disease. Int J Pharm Compd. 2007; 11:20-24 (Pubitemid 46324454)
68. Rapamune (sirolimus) oral suspension and tablets package insert. Philadelphia: Wyeth Pharmaceuticals Inc.; 2005.
69. Giesing DH, Bighley LD, Iles HL. Effect of food and antacid on binding of sucralfate to normal and ulcerated gastric and duodenal mucosa in rats. J Clin Gastroenterol. 1981; 3(suppl 2):111-116
70. Murray M, Grogan TA, Lever J et al. Comparison of tacrolimus absorption in transplant patients receiving continuous versus interrupted enteral nutritional feeding. Ann Pharmacother. 1998; 32:633-6. (Pubitemid 28283845)
71. Prograf (tacrolimus) package insert. Deerfield, IL: Astellas Pharma US, Inc.; 2005.
72. Plezia PM, Thornily SM, Kramer TH et al. The influence of enteral feedings on sustained-release theophylline absorption. Pharmacotherapy. 1990; 10:356-361
73. Gal P, Layson R. Interference with oral theophylline absorption by continuous nasogastric feedings. Ther Drug Monit. 1986; 8:421-423 (Pubitemid 17215856)
74. Elixophylline package insert. St. Louis: Forest Pharmaceuticals, Inc.; 2004.
75. Fish DN, Vidaurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health-Syst Pharm. 1999; 56:1957-60.
76. Valtrex (valacyclovir) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2004.
77. Valcyte (valganciclovir) package insert. Nutley, NJ: Roche Pharmaceuticals; 2003.
78. Anaizi NH, Dentinger PJ, Swenson CF. Stability of valganciclovir in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 2002; 59:1267-1270 (Pubitemid 34747464)
79. Depakene (valproic acid) package insert. North Chicago, IL: Abbott Laboratories; 2006.
80. Vancocin (vancomycin) package insert. Exton, PA: ViroPharma Incorporated; 2005.
81. Purkins L, Wood N, Kleinermans D et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003; 56(suppl 1):17-23. (Pubitemid 37491729)
82. Mohammedi I, Piens MA, Padoin C et al. Plasma levels of voriconazole administered via a nagogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis. 2005; 24:358-360 (Pubitemid 40897526)
83. Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil. 2001; 82:1270-1273
84. Kuhn TA, Garnett WR, Wells BK et al. Recovery of warfarin from an enteral nutrient formula. Am J Health-Syst Pharm. 1989; 46:1395-1399
85. Martin JE, Lutomski DM. Warfarin resistance and enteral feedings. J Parenter Enteral Nutr. 1989; 13:206-208
86. Dickerson RN, Garmon WM, Kuhl DA et al. Vitamin K-independent warfarin resistance after concurrent administration of warfarin and continuous enteral nutrition. Pharmacotherapy. 2008; 28:308-313
87. Mowatt-Larson CA, Brown RO. Specialized nutritional support in respiratory disease. Clin Pharm. 1993; 12:276-292 (Pubitemid 23086246)
88. Kudsk KA, Croce MA, Fabian TC et al. Enteral vs parenteral feeding effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992; 215:503-513
89. Williams NT. Medication administration through enteral feeding tubes. Am J Health-Syst Pharm. 2008; 65:2347-2357